Cipla partners with Qilu Pharmaceutical to license, supply biosimilar Keytruda
Cipla says it has partnered with Qilu Pharmaceutical for licensing and supply of a biosimilar to Keytruda for use in the US.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Cipla partners with Qilu to license Keytruda biosimilar for U.S.
India’s Cipla said its U.S. unit entered an exclusive partnership with China’s Qilu Pharmaceutical to license a biosimilar version of Merck’s Keytruda for the U.S. market.